IP Library Granted Patent US 8,937,158
Granted Patent B2
US 8,937,158 · App. 11/841,654 · Granted Jan 20, 2015

Fc variants with increased affinity for FcγRIIc

Inventors: Gregory Alan Lazar (Los Angeles, CA); Wei Dang (Pasadena, CA); John R. Desjarlais (Pasadena, CA); Sher Bahadur Karki (Pasadena, CA); Omid Vafa (Monrovia, CA); Robert Hayes (Paoli, PA)
Assignee: Xencor, Inc.
C07K16/30C07K16/00C07K16/2863C07K16/2887C07K16/2893C07K16/2896C07K16/32A61K2039/505C07K2317/41C07K2317/71C07K2317/72C07K2317/732C07K2317/734C07K2317/77C07K2317/92C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,937,158
App. No.
11/841,654
Granted
Jan 20, 2015
Kind
B2
Abstract

The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.

Claims (8)

1. A protein comprising an Fc variant of a parent Fc polypeptide, said Fc variant comprising an amino acid substitution selected from the group consisting of 239D and 239E, wherein said Fc variant increases binding affinity to an FcγR as compared to said parent Fc polypeptide and wherein numbering is according to the EU index.

2. The protein of claim 1 , wherein said FcγR is FcγRIIIa.

3. The protein of claim 2 , wherein said FcγRIIIa is of the allotype V158 or F158.

4. The protein of claim 1 , wherein said protein is an antibody or Fc fusion.

5. The protein of claim 1 , wherein said protein is an antibody.

6. The antibody of claim 5 , wherein said antibody has specificity for a target antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, HLA-DR, TNFalpha, MUC18, prostate specific membrane antigen (PMSA) and VEGF.

7. The protein of claim 5 , wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, and a monoclonal antibody.

8. The protein of claim 1 , further comprising a toxin.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2023
From: LAZAR, GREGORY ALAN; DANG, WEI; DESJARLAIS, JOHN R.; KARKI, SHER BAHADUR; VAFA, OMID; HAYES, ROBERT
To: XENCOR, INC.
Reel/Frame 065517/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2023
From: VIELMETTER, JOST
To: XENCOR, INC.
Reel/Frame 065517/0666 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2014
From: LAZAR, GREGORY ALAN; DESJARLAIS, JOHN RUDOLPH; MARSHALL, SHANNON ALICIA; DAHIYAT, BASSIL I.
To: XENCOR, INC.
Reel/Frame 034254/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2014
From: LAZAR, GREGORY ALAN; CHIRINO, ARTHUR J.; DANG, WEI; DESJARLAIS, JOHN RUDOLPH; DOBERSTEIN, STEPHEN KOHL; HAYES, ROBERT J.; KARKI, SHER BAHADUR; VAFA, OMID
To: XENCOR, INC.
Reel/Frame 034254/0768 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2014
From: LAZAR, GREGORY ALAN; CHIRINO, ARTHUR J.; DANG, WEI; DESJARLAIS, JOHN R.; DOBERSTEIN, STEPHEN KOHL; HAYES, ROBERT J.; KARKI, SHER BAHADUR; VAFA, OMID
To: XENCOR, INC.
Reel/Frame 034254/0825 →
Continuity (10)
Continuation 11124620 · May 5, 2005
Continuation In Part 10822231 · Mar 26, 2004
Continuation In Part 10672280 · Sep 26, 2003
Continuation In Part 10379392 · Mar 3, 2003
Provisional Application 60568440 · May 5, 2004
Provisional Application 60589906 · Jul 20, 2004
Provisional Application 60627026 · Nov 9, 2004
Provisional Application 60627774 · Nov 12, 2004
Provisional Application 60626991 · Nov 10, 2004
Related Publication 20080154025A1 · Jun 26, 2008